Elite Pharmaceuticals, Inc. engages in the provision of development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 64 full-time employees. The firm is principally engaged in the development and manufacture of oral, controlled-release products. The firm develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA's) for generic products and New Drug Applications (NDA's) for branded products. The firm owns approximately six different approved ANDA's. The firm's product, SequestOx, is an immediate-release Oxycodone Hydrochloride containing sequestered Naltrexone, which incorporates five milligram, 10 milligram, 15 milligram, 20 milligram and 30 milligram doses of oxycodone into capsules. SequestOx is used for the management of moderate to severe pain where the use of an opioid analgesic is appropriate.